Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. (MRNA) reported that President Stephen Hoge exercised 9,283 Restricted Stock Units on September 1, 2026, converting them into an equal number of common shares. To cover related tax obligations, 4,489 common shares were delivered or withheld at $140.34 per share. Following the RSU conversion, Hoge held 92,828 Restricted Stock Units directly, and also had indirect ownership of common stock through Valhalla, LLC and a family trust, with the trust position reported subject to a Section 16 beneficial ownership disclaimer.
Moderna, Inc. (MRNA) completed a private offering of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including the full exercise of the initial purchasers’ option. The notes are senior unsecured, bear no regular interest and mature on March 1, 2032, unless earlier converted, redeemed or repurchased.
The notes are initially convertible at 4.7487 shares per $1,000 (conversion price about $210.58), a 47.5% premium to the $142.77 MRNA share price on August 27, 2026. Based on this rate, they are convertible into 14,246,100 shares, and in limited cases up to 21,012,600 shares.
Moderna received net proceeds of approximately $2,957.3 million and spent $328.8 million on related capped call transactions with an initial cap price of about $392.62 per share. Remaining proceeds are for general corporate purposes, including potential oncology growth investments and debt repayment. The notes allow conditional conversion and optional redemption after September 6, 2029, and include standard “fundamental change” repurchase protections.
Moderna, Inc. (MRNA) is the issuer for which officer Shannon Thyme Klinger filed a Rule 144 notice covering planned sales of common stock through Fidelity Brokerage Services LLC. The notice relates to 3,471 shares expected to be acquired by stock option exercise and sold for cash on or after 09/01/2026. The filing also cites 399,235,889 common shares outstanding as of 09/01/2026 and reports a prior sale of 3,471 common shares on 06/04/2026 at a stated price of $173,550.00.
For Moderna, Inc. (MRNA), President Stephen Hoge reported the vesting and settlement of restricted stock units into common stock. On August 27 and 28, 2026, RSUs covering a total of 2,048 common shares were converted on a one-for-one basis, and corresponding common shares were acquired. In connection with these vests, a total of 991 common shares were withheld to satisfy tax withholding obligations at prices between about $143 and $150 per share. Following these transactions, Hoge also reports indirect holdings of 4,116 common shares through Valhalla, LLC and 151,933 common shares held by a trust for the benefit of his spouse and children, for which he disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.
Moderna, Inc. (MRNA) reported that Chief Legal Officer Shannon Thyme Klinger had restricted stock units vest and convert into common stock, followed by share withholding for taxes. On August 27 and 28, 2026, a total of 1,103 RSUs were converted into an equal number of common shares, and 535 shares were withheld to satisfy tax withholding obligations. The filing’s Rule 10b5-1 checkbox was not marked, and no post-transaction share balances were reported.
Moderna, Inc. (MRNA) reported that Chief Financial Officer James M. Mock had restricted stock units vest and convert into common stock on August 27 and 28, 2026. A total of 1,103 RSUs were exercised into the same number of common shares. Of these, 535 common shares were delivered or withheld to satisfy tax withholding obligations in connection with the RSU vests, with the remaining shares retained as common stock. The RSUs convert into common stock on a one-for-one basis, under previously granted awards that vest 25% on an initial vest date and then in twelve equal quarterly installments.
Capital World Investors, a division of Capital Research and Management Company and related investment management entities, reported beneficial ownership of 22,276,996 shares of Moderna, Inc. common stock. This represents 5.6% of the 396,786,259 shares believed to be outstanding as of the report.
Capital World Investors has sole voting power over 22,264,639 shares and sole dispositive power over 22,276,996 shares, with no shared voting or dispositive power reported. The filing reflects passive institutional ownership rather than any stated change in control intentions.
Moderna, Inc. CEO Stéphane Bancel reported exercising stock options for 751,715 shares of common stock at $19.15 per share on August 5–6, 2026, ahead of their August 10, 2026 expiration. Pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026, he sold 499,246 shares at weighted-average prices within disclosed ranges from $55.58 to $59.34 solely to cover the option exercise price, withholding taxes, and related transaction costs, and retained the remaining shares acquired in this cashless exercise-and-hold transaction.
FMR LLC filed an amended Schedule 13G reporting a significant ownership position in Moderna Inc. common stock. As of the reporting date, FMR LLC and related entities beneficially owned 51,803,891.34 shares of Moderna common stock, representing 13.1% of the outstanding class.
FMR LLC reported sole voting power over 51,603,918.85 shares and sole dispositive power over 51,803,891.34 shares, with no shared voting or dispositive power. Abigail P. Johnson reported sole dispositive power over the same 51,803,891.34 shares but no voting power. One or more other persons may receive dividends or sale proceeds from these holdings, but no such person holds more than five percent of Moderna’s outstanding common stock.